- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04251247
Diagnostic Value of D-dimer/Fibrinogen Ratio in Patients With Acute Aortic Dissection
March 12, 2024 updated by: Ahmet Can Topcu, Dr. Lutfi Kirdar Kartal Training and Research Hospital
Acute aortic dissection is rare but potentially life-threatening disease with an incidence of 5-30 cases per million, annually.
Therefore prompt diagnosis is crucial.
D-dimer values have been shown to be useful in the diagnosis of acute aortic dissection.
Fibrinogen levels have been shown to be low, normal or high in individuals with acute aortic dissection.
This study aims to investigate whether D-dimer/fibrinogen ratio can be valuable for diagnosis of acute aortic dissection.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
159
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Avni Uygar Seyhan, M.D.
- Phone Number: 30202 902164583000
- Email: uygarseyhan@gmail.com
Study Contact Backup
- Name: Ahmet Can Topcu, M.D.
- Phone Number: 22105 902164583000
- Email: ahmetcan1987@gmail.com
Study Locations
-
-
-
Istanbul, Turkey, 34668
- Recruiting
- Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
-
Contact:
- Ahmet Bolukcu, M.D.
- Phone Number: 4524 902165424444
- Email: ahmetbolukcu@gmail.com
-
Istanbul, Turkey, 34890
- Recruiting
- Kartal Dr. Lutfi Kirdar Training and Research Hospital
-
Contact:
- Avni Uygar Seyhan, M.D.
- Phone Number: 30202 902164583000
- Email: uygarseyhan@gmail.com
-
Contact:
- Ahmet Can Topcu, M.D.
- Phone Number: 22105 902164583000
- Email: ahmetcan1987@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adults presenting to emergency department with chest pain.
Description
Inclusion Criteria:
- Diagnosis of acute aortic dissection
- Diagnosis of acute pulmonary embolism
- Diagnosis of non-cardiac chest pain
Exclusion Criteria:
- Any etiology of chest pain other than acute aortic dissection, acute pulmonary embolism, or non-cardiac chest pain
- Participants who do not give consent for enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Acute aortic dissection
Patients with a diagnosis of acute aortic dissection.
|
The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
|
Acute pulmonary embolism
Patients with a diagnosis of acute pulmonary embolism
|
The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
|
Non-cardiac chest pain
Patients with non-cardiac chest pain
|
The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute aortic dissection
Time Frame: 24 hours
|
Diagnosis of acute aortic dissection confirmed by contrast enhanced computed tomography, magnetic resonance imaging, echocardiography or aortography
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hajsadeghi S, Kerman SR, Khojandi M, Vaferi H, Ramezani R, Jourshari NM, Mousavi SA, Pouraliakbar H. Accuracy of D-dimer:fibrinogen ratio to diagnose pulmonary thromboembolism in patients admitted to intensive care units. Cardiovasc J Afr. 2012 Sep;23(8):446-56. doi: 10.5830/CVJA-2012-041.
- Kara H, Bayir A, Degirmenci S, Kayis SA, Akinci M, Ak A, Celik B, Dogru A, Ozturk B. D-dimer and D-dimer/fibrinogen ratio in predicting pulmonary embolism in patients evaluated in a hospital emergency department. Acta Clin Belg. 2014 Aug;69(4):240-5. doi: 10.1179/2295333714Y.0000000029.
- Guan XL, Wang XL, Liu YY, Lan F, Gong M, Li HY, Liu O, Jiang WJ, Liu YM, Zhu JM, Sun LZ, Zhang HJ. Changes in the Hemostatic System of Patients With Acute Aortic Dissection Undergoing Aortic Arch Surgery. Ann Thorac Surg. 2016 Mar;101(3):945-51. doi: 10.1016/j.athoracsur.2015.08.047. Epub 2015 Oct 23.
- Eggebrecht H, Naber CK, Bruch C, Kroger K, von Birgelen C, Schmermund A, Wichert M, Bartel T, Mann K, Erbel R. Value of plasma fibrin D-dimers for detection of acute aortic dissection. J Am Coll Cardiol. 2004 Aug 18;44(4):804-9. doi: 10.1016/j.jacc.2004.04.053.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2020
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
January 31, 2025
Study Registration Dates
First Submitted
January 30, 2020
First Submitted That Met QC Criteria
January 30, 2020
First Posted (Actual)
January 31, 2020
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 12, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Embolism and Thrombosis
- Aneurysm
- Aortic Diseases
- Dissection, Blood Vessel
- Acute Aortic Syndrome
- Embolism
- Pulmonary Embolism
- Aortic Dissection
- Molecular Mechanisms of Pharmacological Action
- Fibrin Modulating Agents
- Antifibrinolytic Agents
- Hemostatics
- Coagulants
- Fibrin fragment D
Other Study ID Numbers
- 2020/514/169/B
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Embolism
-
Boston Scientific CorporationEKOS CorporationCompletedPulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary EmbolismUnited States
-
Inari MedicalCompletedPulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary EmbolismUnited States
-
Hospital San Carlos, MadridAsociación de Cardiología Intervencionista de la Sociedad Española de CardiologíaRecruitingPulmonary Embolism | Pulmonary Embolism and Thrombosis | Pulmonary Thromboembolisms | Pulmonary Embolism Acute | Pulmonary Embolism Acute MassiveSpain
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Bristol-Myers SquibbCompletedPulmonary Embolism (PE) | Pulmonary ThromboembolismUnited Kingdom
-
Inari MedicalActive, not recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
-
GlaxoSmithKlineCompleted
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedPulmonary Hypertension | Pulmonary ThromboembolismsSpain
-
Victor Tapson, MDBristol-Myers SquibbTerminatedPulmonary Embolism | Right Ventricular Dysfunction | Right Ventricular Failure | Pulmonary Embolism With Acute Cor Pulmonale | Pulmonary Embolism With Pulmonary Infarction | Pulmonary Embolism Subacute MassiveUnited States
-
Imperative Care, Inc.RecruitingCardiovascular Diseases | Vascular Diseases | Embolism | Thrombosis | Thromboembolism | Acute Pulmonary Embolism | Thrombus; Embolism | Emboli, PulmonaryUnited States
Clinical Trials on D-dimer/fibrinogen ratio
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity of BolognaCompletedVenous ThromboembolismItaly
-
Assiut UniversityNot yet recruitingFibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio in Juvenile Idiopathic ArthritisJuvenile Idiopathic Arthritis
-
Assiut UniversityRecruiting
-
Hacettepe UniversityRecruiting
-
Iuliu Hatieganu University of Medicine and PharmacyCompletedCerebral HemorrhageRomania
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)CompletedDeep Vein Thrombosis | Pulmonary EmbolismUnited States, Canada, Ireland, United Kingdom
-
University of Colorado, DenverAmerican Cancer Society, Inc.; Eisai Inc.Completed
-
Hospital of South West JutlandUniversity of Southern DenmarkCompletedMedical Patients in the Emergency DepartmentDenmark
-
Odense University HospitalHolbaek Sygehus; Hospital of South West Jutland; Slagelse SygehusNot yet recruiting